– September 1, 2009
September 1, 2009
View Issues
-
Prostate Cancer in Young Men
Examining SEER data, Lin et al found that young patients with locally advanced or high-grade prostate cancer had shorter overall and prostate cancer-specific survival when compared to similarly staged older patients. -
Arthralgias and Aromatase Inhibition
In a cross-sectional analysis of 300 postmenopausal breast cancer patients treated with aromatase inhibitors, the occurrence of treatment-related arthralgia (by self-report) was approximately 50%. The symptoms were more frequent in women who were closer to the menopause transition and generally occurred within three months after treatment initiation. -
Thrombophilia and Recurrent DVT
Guidelines have suggested patients on warfarin have an international normalized ratio (INR) recall interval not exceeding four weeks. -
PARP Inhibitors: Novel Chemotherapy Finding Its Niche
In an early-phase clinical trial, the PARP inhibitor olaparib was shown to be well- tolerated and safe. Furthermore, for patients who have mutations in BRCA, the majority had either an objective response, as confirmed by imaging studies, or suitable biochemical biomarkers or meaningful stabilization of disease. -
Bariatric Surgery Reduces Cancer Incidence in Women
In a prospective analysis of weight-reduction surgery, the long-term cumulative risk of both non-fatal and fatal cancer was significantly reduced in women, but not in men. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Tamoxifen and CYP2D6 inhibitors, FDA Actions, and FDA Warnings.